Abstract
Treatment for substance abuse and human immunodeficiency virus (HIV) infection historically have come from different providers, often in separate locations, and have been reimbursed through separate funding streams. We describe policy and financing challenges faced by health care providers seeking to integrate buprenorphine, a new treatment for opioid dependence, into HIV primary care. Regulatory challenges include licensing and training restrictions imposed by the Drug Addiction Treatment Act of 2000 and confidentiality regulations for alcohol and drug treatment records. Potential responses include the development of local training programs and electronic medical records. Addressing the complexity of funding sources for integrated care will require administrative support, up-front investments, and federal and state leadership. A policy and financing research agenda should address evidence gaps in the rationales for regulatory restrictions and should include cost-effectiveness studies that quantify the "value for money" of investments in integrated care to improve health outcomes for HIV-infected patients with opioid dependence.
| Original language | English (US) |
|---|---|
| Journal | Clinical Infectious Diseases |
| Volume | 43 |
| Issue number | SUPPL. 4 |
| DOIs | |
| State | Published - Dec 15 2006 |
Fingerprint
ASJC Scopus subject areas
- Immunology
Cite this
Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. / Schackman, Bruce R.; Merrill, Joseph O.; McCarty, Dennis; Levi, Jeffrey; Lubinski, Christine.
In: Clinical Infectious Diseases, Vol. 43, No. SUPPL. 4, 15.12.2006.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care
AU - Schackman, Bruce R.
AU - Merrill, Joseph O.
AU - McCarty, Dennis
AU - Levi, Jeffrey
AU - Lubinski, Christine
PY - 2006/12/15
Y1 - 2006/12/15
N2 - Treatment for substance abuse and human immunodeficiency virus (HIV) infection historically have come from different providers, often in separate locations, and have been reimbursed through separate funding streams. We describe policy and financing challenges faced by health care providers seeking to integrate buprenorphine, a new treatment for opioid dependence, into HIV primary care. Regulatory challenges include licensing and training restrictions imposed by the Drug Addiction Treatment Act of 2000 and confidentiality regulations for alcohol and drug treatment records. Potential responses include the development of local training programs and electronic medical records. Addressing the complexity of funding sources for integrated care will require administrative support, up-front investments, and federal and state leadership. A policy and financing research agenda should address evidence gaps in the rationales for regulatory restrictions and should include cost-effectiveness studies that quantify the "value for money" of investments in integrated care to improve health outcomes for HIV-infected patients with opioid dependence.
AB - Treatment for substance abuse and human immunodeficiency virus (HIV) infection historically have come from different providers, often in separate locations, and have been reimbursed through separate funding streams. We describe policy and financing challenges faced by health care providers seeking to integrate buprenorphine, a new treatment for opioid dependence, into HIV primary care. Regulatory challenges include licensing and training restrictions imposed by the Drug Addiction Treatment Act of 2000 and confidentiality regulations for alcohol and drug treatment records. Potential responses include the development of local training programs and electronic medical records. Addressing the complexity of funding sources for integrated care will require administrative support, up-front investments, and federal and state leadership. A policy and financing research agenda should address evidence gaps in the rationales for regulatory restrictions and should include cost-effectiveness studies that quantify the "value for money" of investments in integrated care to improve health outcomes for HIV-infected patients with opioid dependence.
UR - http://www.scopus.com/inward/record.url?scp=33845418372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845418372&partnerID=8YFLogxK
U2 - 10.1086/508190
DO - 10.1086/508190
M3 - Article
C2 - 17109311
AN - SCOPUS:33845418372
VL - 43
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - SUPPL. 4
ER -